LONA LeonaBio (LONA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001620463
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
15
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $777 priced
What the filings say about LONA
Activist stakes (13D), 180 days
1 filing
Largest: 36.9% of the class
LeonaBio insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for LeonaBio, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 8.9% of the 57,926 shares held after it.
- 4 other insiders sold within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT and CEO Litton Mark James sold about $27.7K of LONA on Mar 4, 2026, the largest insider sale at the company on our record; 4 other insiders sold within 30 days and 15 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 5.7% of the 15,851 shares held after it.
- 4 other insiders sold within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER Renninger Robert sold about $4.9K of LONA on Mar 4, 2026, the largest insider sale at the company on our record; 4 other insiders sold within 30 days and 15 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 7.2% of the 18,376 shares held after it.
- 4 other insiders sold within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: GENERAL COUNSEL and CCO Worthington Mark sold about $7.1K of LONA on Mar 4, 2026, the largest insider sale at the company on our record; 4 other insiders sold within 30 days and 15 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 5.4% of the 25,178 shares held after it.
- 4 other insiders sold within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF SCIENTIFIC OFFICER CHURCH KEVIN sold about $7.3K of LONA on Mar 4, 2026, the largest insider sale at the company on our record; 4 other insiders sold within 30 days and 15 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 10.8% of the 15,887 shares held after it.
- 4 other insiders sold within 30 days.
- 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF MEDICAL OFFICER San Martin Javier sold about $9.2K of LONA on Mar 4, 2026, the largest insider sale at the company on our record; 4 other insiders sold within 30 days and 15 funds added in the latest 13F quarter.5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
15 funds bought in last quarter
below 73% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.4% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 87% of Pharma & Biotech
The situation: each line is one rule over one dataset
Sermonix Pharmaceuticals, Inc. disclosed a 5%+ stake (36.9%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch LONA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+23.2%12M
Insider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns LONA: institutional holders (13F)
13F holdings, latest reported quarter
1,859,322 sh
$17.1M
787,402 sh
$7.2M
777,100 sh
$7.1M
634,539 sh
$5.8M
464,398 sh
$4.3M
Congress trades in LONA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Sermonix Pharmaceuticals, Inc.
Activist 13D · 2026-08-31
36.9%
Portman David J.
Activist 13D · 2026-08-31
36.9%
LONA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
LONA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$1.4M position · as of 2026-06-30
1.8%
iShares Micro-Cap ETF
$199.8K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$13.0K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$342.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$757.2K position · as of 2026-06-30
0.0%
Dimensional US Core Equity 1 ETF
$18.5K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
0 active
2
Phase 2
0 active
1
Phase 3
1 active
2
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.4M
$2.0M
$770.8K
-69%
n/a
2024
$3.2M
$1.2M
$1.4M
-76%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 15 funds added last quarter. Each figure is a federal filing, dated the day it went public.
LONA financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM LONA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM LONA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$62.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM LONA
| FY Dec 2025 | -$45.8M |
| FY Dec 2024 | -$97.2M |
| FY Dec 2023 | -$101.1M |
| FY Dec 2022 | -$73.6M |
| FY Dec 2021 | -$44.7M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$26.0M |
| Sep 2024 | -$23.0M |
At each fiscal year end
Single quarter
Debt to equity
0.05x
long-term debt only, 2019-12-31 (79 months older than the period end); equity 2026-06-30
Debt to equity LONA
| FY Dec 2025 | 0.06x |
| FY Dec 2024 | 0.03x |
| FY Dec 2023 | 0.01x |
| FY Dec 2022 | 0.01x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.05x |
| Mar 2026 | 0.03x |
| Dec 2025 | 0.06x |
| Sep 2025 | 0.06x |
| Jun 2025 | 0.05x |
| Mar 2025 | 0.04x |
| Dec 2024 | 0.03x |
| Sep 2024 | 0.03x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-39.88x
TTM operating cash flow over long-term debt only, 2019-12-31 (79 months older than the period end)
Cash flow to debt LONA
| FY Dec 2025 | -29.45x |
| FY Dec 2024 | -62.57x |
| FY Dec 2023 | -64.88x |
| FY Dec 2022 | -46.66x |
| FY Dec 2021 | -27.75x |
| Jun 2026 | -39.88x |
| Mar 2026 | -33.46x |
| Dec 2025 | -29.45x |
| Sep 2025 | -33.71x |
| Jun 2025 | -45.52x |
| Mar 2025 | -55.40x |
| Dec 2024 | -62.57x |
| Sep 2024 | -62.75x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-432.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity LONA
| FY Dec 2025 | -291.9% |
| FY Dec 2024 | -110.8% |
| FY Dec 2023 | -64.4% |
| FY Dec 2022 | -34.4% |
| FY Dec 2021 | -18.4% |
| Jun 2026 | -432.6% |
| Mar 2026 | -299.7% |
| Dec 2025 | -291.9% |
| Sep 2025 | -89.6% |
| Jun 2025 | -103.9% |
| Mar 2025 | -110.8% |
| Dec 2024 | -110.8% |
| Sep 2024 | -102.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-306.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets LONA
| FY Dec 2025 | -140.5% |
| FY Dec 2024 | -88.6% |
| FY Dec 2023 | -56.2% |
| FY Dec 2022 | -32.4% |
| FY Dec 2021 | -17.9% |
| Jun 2026 | -306.9% |
| Mar 2026 | -225.5% |
| Dec 2025 | -140.5% |
| Sep 2025 | -65.0% |
| Jun 2025 | -81.6% |
| Mar 2025 | -90.2% |
| Dec 2024 | -88.6% |
| Sep 2024 | -80.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital LONA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-299.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed LONA
| FY Dec 2025 | -226.5% |
| FY Dec 2024 | -114.0% |
| FY Dec 2023 | -68.2% |
| FY Dec 2022 | -37.2% |
| FY Dec 2021 | -21.4% |
| Jun 2026 | -299.1% |
| Mar 2026 | -213.6% |
| Dec 2025 | -226.5% |
| Sep 2025 | -91.6% |
| Jun 2025 | -106.1% |
| Mar 2025 | -113.5% |
| Dec 2024 | -114.0% |
| Sep 2024 | -106.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing LONA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$14.8M
market value at close 2026-10-23 on 2026-08-04 shares, plus long-term debt only, 2019-12-31 (79 months older than the period end), minus cash 2026-06-30
Enterprise value LONA
| FY Dec 2025 | -$37.9M |
| FY Dec 2024 | $180.1M |
| FY Dec 2023 | $835.7M |
| FY Dec 2022 | $1.1B |
| FY Dec 2021 | $4.8B |
| Jun 2026 | $55.6M |
| Mar 2026 | $9.3M |
| Dec 2025 | -$37.9M |
| Sep 2025 | $144.0M |
| Jun 2025 | $99.6M |
| Mar 2025 | $86.4M |
| Dec 2024 | $180.1M |
| Sep 2024 | $104.1M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-135.9%
TTM free cash flow over market value at close 2026-10-23
FCF yield LONA
| FY Dec 2025 | -153.3% |
| FY Dec 2024 | -42.8% |
| FY Dec 2023 | -10.9% |
| FY Dec 2022 | -6.1% |
| FY Dec 2021 | -0.9% |
| Jun 2026 | -71.8% |
| Mar 2026 | -128.3% |
| Dec 2025 | -153.3% |
| Sep 2025 | -32.1% |
| Jun 2025 | -60.0% |
| Mar 2025 | -77.3% |
| Dec 2024 | -42.8% |
| Sep 2024 | -56.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing LONA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$102.3M | -$100.9M | -$125.5M | -$104.0M |
| Net income | -$106.0M | -$97.0M | -$117.7M | -$95.6M |
| EPS (diluted) | -24.70 | -25.19 | -3.09 | -2.53 |
| Operating cash flow | -$45.7M | -$97.2M | -$100.8M | -$72.5M |
| Cash | $69.3M | $48.4M | $90.6M | $96.0M |
SEC XBRL, fiscal years, as known on 2026-10-27
LONA Stock Sonar score 4/7 axes
Find similar shapesCompareLONA ranks highest on risk and compliance (87th percentile) and financial health (39th), and lowest on profitability (7th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
LONA filings, in plain words
Read the full summary
1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 36.9% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
